Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 649 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eczema, Atopic Clear all
Completed Phase 2 Interventional Results available

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

NCT05186805
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Thousand Oaks, California • Centennial, Colorado • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)

NCT04011215
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
wool clothing, standard clothing
Other
Lead sponsor
Murdoch Childrens Research Institute
Other
Eligibility
3 Months to 5 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Recruiting Phase 2 Interventional

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions
Camoteskimab, Placebo
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160
View directory record Official record
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

NCT05870865
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus
Interventions
ASN008, ASN008 Matching Vehicle
Drug · Other
Lead sponsor
Formation Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Interferon Responses in Eczema Herpeticum

NCT01429311
View directory record Official record
Conditions
Atopic Dermatitis, Eczema Herpeticum, Herpes Simplex Infections, Eczema Vaccinatum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PRN473 (SAR444727), Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT06058156
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
SAR444656 (KT-474), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Scottsdale, Arizona • Boynton Beach, Florida • Doral, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)

NCT06101823
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OpSCF, Placebo
Biological
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Terminated No phase listed Observational

A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

NCT00475605
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
LEO Pharma
Industry
Eligibility
Up to 16 Years
Enrollment
8,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
198
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

NCT07172321
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745638
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 9, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

NCT06300697
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergy, Healthy
Interventions
Data and biospecimen collection, Skin biopsies, Oral Food Challenge (OFC) procedures
Other
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Not applicable Interventional

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

NCT06275659
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
CT-100-004-A, CT-100-004-B
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

NCT04060550
View directory record Official record
Conditions
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
Interventions
Xolair
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
16 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 9, 2026, 5:02 PM EDT
Active, not recruiting Phase 4 Interventional

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

NCT06906497
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
lebrikizumab
Drug
Lead sponsor
Johann E Gudjonsson MD PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Folsom, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

NCT01139450
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 2 Interventional

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

NCT06810050
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo)
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Fremont, California • Manhattan Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of CEE321 in Adult Subjects

NCT04612062
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CEE321
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

NCT01941537
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ILV-094, Placebo Comparator
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

NCT01702181
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OPA-15406, Tacrolimus, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 9, 2026, 5:02 PM EDT
Recruiting Phase 2 Interventional

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
APG777
Drug
Lead sponsor
Apogee Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 9, 2026, 5:02 PM EDT